Chromatin biomarkers linked to prognosis in non-functional pancreatic neuroendocrine tumors
Official title: The Prognostic Significance and Mechanistic Determination of Chromatin Regulatory Biomarkers in Non-Functional Pancreatic Neuroendocrine Tumors
Funded at University of Pittsburgh at Pittsburgh · NIH-11293502 · Data updated 2026-11-12
A study exploring chromatin-related biomarkers to better predict which non-functional pancreatic neuroendocrine tumors may behave aggressively.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | July 15, 2021 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $532,490 |
| NIH project number | 4R37CA263622-06 |
| Project ID | NIH-11293502 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients diagnosed with non-functional pancreatic neuroendocrine tumors who are undergoing tumor profiling or have available tumor samples for analysis.
✕Less likely to help
Patients whose tumors do not show the identified chromatin alterations may not benefit from the new biomarkers.
What this research studies
This project looks at stubborn pancreatic tumors that don’t make hormones and tries to find markers in the tumor’s chromatin that signal which tumors will spread. Researchers will analyze genomic and epigenetic changes in tumor samples from patients, aiming to link these markers with disease progression. The goal is to improve how doctors predict outcomes and tailor treatment for each patient in real-world care. The work builds on prior findings about ATRX/DAXX and other chromatin-related alterations and uses a multinational patient cohort to validate new biomarkers.
Why it matters
Potential benefit: If successful, patients could receive more accurate prognostic information and more personalized treatment plans.
How similar studies have gone: Previous work has linked ATRX/DAXX alterations to metastasis in NF-PanNETs; this study extends that to additional chromatin-related changes and broader cohorts, with mixed but promising early signals.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Singhi, Aatur Dilip — University of Pittsburgh at Pittsburgh
- Study coordinator: Singhi, Aatur Dilip
Related research
Other NIH-funded projects on the same topics.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Enteric glial cell reprogramming and MENIN loss in dpNETs
A study to understand how losing a gene called MENIN in gut-supporting glial cells might turn them into neuroendocrine tumor cells in people with MEN1.
-
Targeting CXCR4 and redox metabolism to treat lung neuroendocrine cancers with targeted alpha therapy
Aims to develop a new alpha-particle therapy approach for hard-to-treat lung neuroendocrine tumors by attacking CXCR4 and redox pathways.
-
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
This project tests a new targeted radiotherapy approach for neuroendocrine tumors to maximize tumor response while protecting kidneys.
-
SSTR2 imaging to guide pituitary tumor radiotherapy and planning
This project tests a PET/MRI imaging approach to map somatostatin receptor 2 in pituitary neuroendocrine tumors to help tailor radiation therapy for better tumor control.
-
Receptor-targeted fluorescent guidance for pancreatic neuroendocrine tumor surgery
A new fluorescent dye that sticks to pancreatic neuroendocrine tumors is being developed to help surgeons see and remove tumors more clearly during surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.